LON:INDV Indivior (INDV) Share Price, News & Analysis GBX 987 +25.50 (+2.65%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 958▼ 1,01350-Day Range 756.50▼ 1,44552-Week Range 653▼ 1,927Volume941,812 shsAverage Volume562,394 shsMarket Capitalization£1.33 billionP/E Ratio32,900.00Dividend Yield1.52%Price TargetGBX 2,100 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.8% UpsideGBX 2,100 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.71Based on 12 Articles This WeekInsider TradingAcquiring Shares£1.50 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.05 out of 5 stars 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 1 research reports in the past 90 days.Read more about Indivior's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for INDV. Previous Next 1.7 Dividend Strength Dividend LeadershipIndivior is a leading dividend payer. It pays a dividend yield of 4.48%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthIndivior does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Indivior is 50,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Indivior's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 3.2 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Indivior this week, compared to 0 articles on an average week.Search Interest3 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Indivior to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have bought more of their company's stock than they have sold. Specifically, they have bought £14,989.40 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 3.25% of the stock of Indivior is held by insiders.Percentage Held by Institutions85.55% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 32,900.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 142.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 32,900.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 156.32.Price to Earnings Growth RatioDue to a projected decrease in earnings for Indivior, their PEG ratio cannot be calculated.Price to Book Value per Share RatioIndivior has a P/B Ratio of 141.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Indivior Stock (LON:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesJuly 25 at 10:42 PM | seekingalpha.comIndivior PLC (INDV) Q2 2024 Earnings Call TranscriptJuly 25 at 10:42 PM | markets.businessinsider.comIndivior’s Strong Q2 Performance and Positive Outlook Prompt Buy RatingJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 25 at 8:16 AM | marketwatch.comIndivior Shares Jump on Increased Revenue, $100M Share BuybackJuly 25 at 8:16 AM | reuters.comIndivior announces $100 mln share buyback; shares jumpJuly 25 at 8:16 AM | msn.comINDV Stock Earnings: Indivior Beats EPS, Beats Revenue for Q2 2024July 25 at 8:16 AM | benzinga.comWhy Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketJuly 25 at 6:32 AM | americanbankingnews.comIndivior (LON:INDV) Reaches New 52-Week Low at $8.03July 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 25 at 5:16 AM | americanbankingnews.comIndivior (LON:INDV) Trading Up 16.9%July 23 at 3:09 PM | markets.businessinsider.comBuy Rating Affirmed for Indivior: Long-Term Growth Potential Despite Short-Term SetbacksJuly 23 at 3:09 PM | msn.comIndivior draws a bullish view at Piper Sandler after the selloffMay 23, 2024 | marketwatch.comIndivior Shareholders Approve Main Listing Switch to U.S.May 1, 2024 | lse.co.ukLondon open: FTSE edges higher ahead of Fed; Nationwide data in focusApril 26, 2024 | finance.yahoo.comWhy Indivior PLC (LON:INDV) Looks Like A Quality CompanyApril 14, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - INDVMarch 12, 2024 | msn.comThis Nasal Spray Rapidly Reverses Effects Of Fentanyl Overdose And No, It's Not NaloxoneFebruary 29, 2024 | markets.businessinsider.comIndivior Says Final Court Approval Concludes Antitrust Multidistrict LitigationSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:INDV CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,100 High Stock Price TargetGBX 2,700 Low Stock Price TargetGBX 1,500 Potential Upside/Downside+112.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.03 Trailing P/E Ratio32,900.00 Forward P/E Ratio931.13 P/E Growth-5.57Net Income£5 million Net Margins0.44% Pretax MarginN/A Return on Equity12.20% Return on Assets9.94% Debt Debt-to-Equity Ratio2,790.00 Current Ratio0.93 Quick Ratio1.52 Sales & Book Value Annual Sales£1.12 billion Price / Sales1.19 Cash FlowGBX 368.27 per share Price / Cash Flow2.68 Book ValueGBX 7 per share Price / Book141.00Miscellaneous Outstanding Shares135,140,000Free FloatN/AMarket Cap£1.33 billion OptionableNot Optionable Beta0.06 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsHikma PharmaceuticalsLON:HIKHUTCHMEDLON:HCMAmryt PharmaLON:AMYTBenchmarkLON:BMKAllergy TherapeuticsLON:AGYView All CompetitorsInsidersJo Le CouilliardBought 1,490 shares on 7/26/2024Total: £1.50 M ($1,006.00/share)Mark CrossleySold 10,549 sharesTotal: £17.06 M ($1,617.00/share)Mark CrossleySold 15,444 sharesTotal: £25.39 M ($1,644.00/share)Graham HetheringtonBought 1,743 shares on 12/20/2023Total: £2.07 M ($1,189.00/share)Graham HetheringtonBought 2,650 shares on 11/20/2023Total: £3.58 M ($1,350.00/share)View All Insider Transactions INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at GBX 1,185 at the start of the year. Since then, INDV stock has decreased by 16.7% and is now trading at GBX 987. View the best growth stocks for 2024 here. How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK) and Bodycote (BOY). This page (LON:INDV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDV Stock Alerts